ABVC BioPharma, Inc. (ABVC) Balance Sheet
ABVC balance sheet, 2025
December 31, 2025 · U.S. dollars$21.1M assets = $7.8M liabilities + $13.3M equity
Both columns are drawn to the same scale: what ABVC owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ABVC financial health
Descriptive bands, not a rating. Fiscal 2025.
ABVC balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $18,6452016 | $21.1M2025 | +118.4%/yr | |
| Total liabilities | $6.5M2016 | $7.8M2025 | +1.9%/yr | |
| Shareholders’ equity | −$6.5M2016 | $11.1M2025 | — | |
| Cash & short-term investments | $18,6452016 | $745,8342025 | +50.7%/yr | |
| Total debt | $02016 | $3.5M2025 | — | |
| Net cash (debt) | $18,6452016 | −$2.7M2025 | −$2.7M | |
| Working capital | −$6.5M2016 | −$3.7M2025 | +$2.9M | |
| Book value per share | $0.112024 | $0.482025 | +354.9%/yr | |
| Current ratio | 0.002016 | 0.412025 | +0.40 | |
| Debt / equity | 0.742017 | 0.312025 | −0.43 | |
| Shares outstanding | 11.7M2024 | 23.3M2025 | +99.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ABVC assets
ABVC liabilities and equity
ABVC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ABVC balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $745,834 | $928,551 | $796,092 | $1.5M | $5.9M | $5.0M | $144,295 | $40,044 | $256,925 | $18,645 |
| Cash & equivalents | $681,480 | $863,815 | $716,780 | $1.4M | $5.8M | $5.0M | $144,295 | $40,044 | $256,925 | $18,645 |
| Short-term investments | $64,354 | $64,736 | $79,312 | $75,797 | $108,147 | $1.2M | $3.4M | $0 | $0 | $0 |
| Receivables | $763,388 | $1.2M | $759,566 | $1.4M | $426,091 | $999,402 | $640,526 | $14,639 | $2.5M | $0 |
| Inventory | $0 | $0 | $0 | $1.3M | $25,975 | −$839,690 | −$476,960 | $1,318 | $199,708 | $0 |
| Other current assets | $992,121 | $96,213 | $101,051 | $0 | $1.3M | $1.0M | $570,377 | $40,272 | $0 | $0 |
| Total current assets | $2.5M | $2.2M | $1.7M | $3.0M | $7.7M | $6.2M | $878,238 | $96,273 | $760,973 | $18,645 |
| Property, plant & equipment (net) | $14.7M | $1.2M | $1.4M | $1.7M | $2.0M | $2.3M | $1.0M | $510,066 | $570,576 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $1.9M | $2.3M | $2.5M | $842,070 | $932,755 | $1.2M | $3.4M | $0 | $4.2M | $0 |
| Other non-current assets | $1.9M | $1.9M | $2.2M | $5.4M | $3.1M | $5.1M | $1.6M | $0 | $1.1M | $0 |
| Total assets | $21.1M | $7.5M | $7.8M | $10.9M | $13.7M | $14.8M | $6.9M | $96,273 | $6.6M | $18,645 |
| Liabilities | ||||||||||
| Accounts payable | — | — | $112,946 | — | $0 | $23,044 | $23,995 | $14,639 | $0 | $18,370 |
| Short-term debt | $1.9M | $3.0M | $2.4M | $2.6M | $2.2M | $2.7M | $4.3M | $550,000 | $1.1M | $0 |
| Deferred revenue | — | $81,115 | $79,500 | $10,985 | $10,985 | $12,070 | $13,085 | — | — | — |
| Total current liabilities | $6.2M | $6.6M | $6.1M | $5.5M | $3.7M | $4.8M | $6.8M | $5.6M | $4.1M | $6.5M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $2.6M | $0 | $250,000 | $55,690 | $0 |
| Lease obligations | $1.9M | $640,388 | $809,283 | $1.2M | $1.5M | $1.8M | $539,803 | — | — | — |
| Other long-term liabilities | $1.6M | $258,486 | $429,136 | $799,807 | $1.1M | $1.5M | $238,435 | $27,467 | $0 | $60 |
| Total liabilities | $7.8M | $6.8M | $6.5M | $6.3M | $4.8M | $8.9M | $7.1M | $5.8M | $4.1M | $6.5M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $25,053 | $13,868 | $7,940 | $3,286 | $28,926 | $24,420 | $19,478 | $213,927 | $4,121 | $210,822 |
| Retained earnings (deficit) | −$76.9M | −$68.9M | −$64.0M | −$54.9M | −$38.5M | −$25.6M | −$15.9M | −$19.9M | −$10.0M | −$11.5M |
| Treasury stock | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Accumulated other comprehensive income | $487,602 | $476,705 | $516,387 | $517,128 | −$1.7M | $564,860 | $663,753 | $1.0M | $757,327 | $0 |
| Minority interest | $2.2M | −$502,181 | −$300,637 | $137,554 | — | — | — | $0 | $0 | $0 |
| Total shareholders' equity | $11.1M | $1.2M | $1.6M | $4.5M | $8.8M | $6.6M | −$150,964 | −$5.7M | $1.7M | −$6.5M |
| Key figures | ||||||||||
| Total debt | $3.5M | $3.2M | $2.8M | $3.4M | $3.3M | $6.8M | $4.6M | $800,000 | $1.2M | $0 |
| Net cash (debt) | −$2.7M | −$2.3M | −$2.0M | −$1.9M | $2.6M | −$1.8M | −$4.4M | −$759,956 | −$969,197 | $18,645 |
| Working capital | −$3.7M | −$4.4M | −$4.4M | −$2.6M | $4.0M | $1.3M | −$5.9M | −$5.5M | −$3.3M | −$6.5M |
| Tangible book value | $11.1M | $1.2M | $1.6M | $4.5M | $8.8M | $6.6M | −$150,964 | −$5.7M | $1.7M | −$6.5M |
| Book value per share | $0.48 | $0.11 | — | — | — | — | — | — | — | — |
| Shares outstanding | 23.3M | 11.7M | — | — | — | — | — | — | — | — |
| Current ratio | 0.41 | 0.33 | 0.27 | 0.54 | 2.07 | 1.27 | 0.13 | 0.02 | 0.19 | 0.00 |
| Quick ratio | 0.24 | 0.32 | 0.25 | 0.51 | 1.72 | 1.24 | 0.12 | 0.01 | 0.69 | 0.00 |
| Debt / equity | 0.31 | 2.61 | 1.78 | 0.77 | 0.38 | 1.03 | — | — | 0.74 | — |
| Equity / assets | 52.8% | 16.3% | 20.0% | 40.7% | 64.6% | 44.7% | −2.2% | −5,972.0% | 25.0% | −34,966.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $94,364 | $202,509 | $745,834 | $257,243 | $1.1M | $824,620 | $313,118 | $840,682 | $818,452 | $734,918 | $796,092 | $1.2M |
| Cash & equivalents | $31,944 | $140,324 | $681,480 | $192,068 | $1.1M | $759,568 | $248,382 | $769,873 | $742,769 | $659,002 | $716,780 | $1.1M |
| Short-term investments | $62,420 | $62,185 | $64,354 | $65,175 | $65,211 | $65,052 | $64,736 | $70,809 | $75,683 | $75,916 | $79,312 | $68,521 |
| Receivables | $29,462 | $196,322 | $763,388 | $2.7M | $1.4M | $537,119 | $0 | $1.2M | $1.3M | $899,930 | $759,566 | $1.2M |
| Inventory | $0 | $0 | $0 | $11,460 | $11,460 | $11,460 | $0 | −$101,754 | $0 | $0 | $0 | $620,868 |
| Other current assets | $287,903 | $250,017 | $992,121 | $1.1M | $194,999 | $96,362 | $1.9M | $193,045 | $100,810 | $159,602 | $101,051 | $0 |
| Total current assets | $411,729 | $648,848 | $2.5M | $4.1M | $2.8M | $1.5M | $2.2M | $2.1M | $2.2M | $1.8M | $1.7M | $2.5M |
| Property, plant & equipment (net) | $14.6M | $14.6M | $14.7M | $12.4M | $8.7M | $8.7M | $1.2M | $8.4M | $8.5M | $8.7M | $1.4M | $8.9M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $2.5M | $1.8M | $1.9M | $2.7M | $2.8M | $2.8M | $2.3M | $2.3M | $2.4M | $2.5M | $2.5M | $2.7M |
| Other non-current assets | $1.9M | $2.6M | $1.9M | $1.9M | $2.0M | $1.9M | $1.9M | $1.5M | $1.5M | $1.8M | $2.2M | $3.2M |
| Total assets | $19.4M | $19.7M | $21.1M | $21.2M | $16.2M | $14.9M | $7.5M | $14.5M | $14.6M | $14.7M | $7.8M | $17.3M |
| Liabilities | ||||||||||||
| Accounts payable | — | — | — | — | — | — | — | — | — | $108,110 | $112,946 | −$79,501 |
| Short-term debt | $358,107 | $1.2M | $1.9M | $1.2M | $2.1M | $2.8M | — | $2.6M | $2.5M | $2.4M | $2.4M | $1.7M |
| Deferred revenue | $12,600 | — | — | — | $81,115 | $81,115 | — | $79,500 | $79,500 | $79,500 | $79,500 | $79,501 |
| Total current liabilities | $5.7M | $5.4M | $6.2M | $6.5M | $6.5M | $6.7M | $6.6M | $6.3M | $6.5M | $6.6M | $6.1M | $5.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.7M |
| Lease obligations | $1.8M | $1.8M | $1.9M | $363,407 | $459,325 | $533,460 | $640,388 | $507,659 | $607,001 | $708,023 | $809,283 | $899,817 |
| Other long-term liabilities | $1.4M | $1.5M | $1.6M | $176,072 | $218,812 | $188,665 | $258,487 | $167,880 | $256,482 | $339,833 | $429,136 | $512,831 |
| Total liabilities | $7.1M | $6.9M | $7.8M | $6.7M | $6.8M | $6.9M | $6.8M | $6.5M | $6.8M | $7.0M | $6.5M | $7.5M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $26,220 | $25,767 | $25,053 | $24,190 | $19,533 | $15,378 | — | $12,712 | $12,052 | $10,698 | $7,940 | $4,823 |
| Retained earnings (deficit) | −$79.2M | −$78.4M | −$76.9M | −$73.3M | −$72.0M | −$69.8M | −$68.9M | −$70.6M | −$70.4M | −$69.4M | −$64.0M | −$62.3M |
| Accumulated other comprehensive income | $498,193 | $499,650 | $487,602 | $487,048 | $1.6M | $475,212 | — | $492,322 | $466,932 | $233,323 | $516,387 | $519,123 |
| Minority interest | $2.0M | $2.1M | $2.2M | $2.4M | $2.5M | — | — | — | — | — | — | — |
| Total shareholders' equity | $10.3M | $10.8M | $11.1M | $12.1M | $7.0M | $5.4M | $1.2M | $8.4M | $8.3M | $8.0M | $1.6M | $9.8M |
| Key figures | ||||||||||||
| Total debt | $1.8M | $2.7M | $3.5M | $1.4M | $2.3M | $3.0M | — | $2.7M | $2.7M | $2.7M | $2.8M | $3.9M |
| Net cash (debt) | −$1.7M | −$2.5M | −$2.7M | −$1.1M | −$1.2M | −$2.2M | — | −$1.9M | −$1.9M | −$2.0M | −$2.0M | −$2.7M |
| Working capital | −$5.3M | −$4.7M | −$3.7M | −$2.4M | −$3.8M | −$5.3M | −$4.4M | −$4.2M | −$4.4M | −$4.8M | −$4.4M | −$2.9M |
| Tangible book value | $10.3M | $10.8M | $11.1M | $12.1M | $7.0M | $5.4M | $1.2M | $8.4M | $8.3M | $8.0M | $1.6M | $9.8M |
| Book value per share | $0.39 | $0.42 | $0.48 | $0.52 | $0.40 | $0.36 | $0.09 | $0.67 | $0.73 | $0.82 | $0.22 | — |
| Shares outstanding | 26.1M | 25.4M | 23.3M | 23.3M | 17.4M | 15.0M | 13.1M | 12.4M | 11.3M | 9.7M | 7.0M | — |
| Current ratio | 0.07 | 0.12 | 0.41 | 0.63 | 0.42 | 0.22 | 0.33 | 0.34 | 0.33 | 0.27 | 0.27 | 0.46 |
| Quick ratio | 0.02 | 0.07 | 0.24 | 0.45 | 0.39 | 0.20 | 0.05 | 0.33 | 0.32 | 0.25 | 0.25 | 0.44 |
| Debt / equity | 0.17 | 0.25 | 0.31 | 0.12 | 0.33 | 0.55 | — | 0.33 | 0.33 | 0.34 | 1.78 | 0.40 |
| Equity / assets | 53.0% | 54.6% | 52.8% | 56.9% | 43.2% | 36.3% | 16.3% | 57.8% | 56.7% | 54.6% | 20.0% | 56.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 3, 2026); data from EODHD.
ABVC financial position
At the end of fiscal 2025 (December 31, 2025), ABVC BioPharma had total assets of $21.1 million (up 179.3% from a year earlier), total liabilities of $7.8 million and shareholders' equity of $11.1 million. It held $0.7 million in cash and short-term investments against $3.5 million of debt, net debt of $2.7 million. Its current ratio was 0.41. In the latest quarter (ended June 30, 2026) total assets were $19.4 million and equity $10.3 million.
Related: ABVC income statement, ABVC cash flow statement, ABVC key metrics. See the ABVC stock overview for the latest quote and news.
ABVC balance sheet FAQ
What are ABVC BioPharma's total assets?
ABVC BioPharma reported total assets of $21.1 million at the end of fiscal 2025 (December 31, 2025), compared with $7.5 million a year earlier.
How much debt does ABVC BioPharma have?
ABVC BioPharma had $3.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.31.
How much cash does ABVC BioPharma have?
ABVC BioPharma held $0.7 million in cash and short-term investments at the end of fiscal 2025; with $3.5 million of debt that is net debt of $2.7 million.
What is ABVC BioPharma's book value?
ABVC BioPharma's shareholders' equity (book value) was $11.1 million at the end of fiscal 2025, or $0.48 per share.
What is ABVC BioPharma's current ratio?
ABVC BioPharma had current assets of $2.5 million and current liabilities of $6.2 million, a current ratio of 0.41 (current liabilities exceed current assets).